AU2010325960C1 - Amantadine compositions and methods of use - Google Patents
Amantadine compositions and methods of use Download PDFInfo
- Publication number
- AU2010325960C1 AU2010325960C1 AU2010325960A AU2010325960A AU2010325960C1 AU 2010325960 C1 AU2010325960 C1 AU 2010325960C1 AU 2010325960 A AU2010325960 A AU 2010325960A AU 2010325960 A AU2010325960 A AU 2010325960A AU 2010325960 C1 AU2010325960 C1 AU 2010325960C1
- Authority
- AU
- Australia
- Prior art keywords
- amantadine
- composition
- hours
- administration
- plasma concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 title claims abstract description 522
- 229960003805 amantadine Drugs 0.000 title claims abstract description 520
- 239000000203 mixture Substances 0.000 title claims abstract description 426
- 238000000034 method Methods 0.000 title claims abstract description 86
- 238000013265 extended release Methods 0.000 claims abstract description 245
- 238000011282 treatment Methods 0.000 claims abstract description 61
- 230000036470 plasma concentration Effects 0.000 claims description 131
- 150000003839 salts Chemical class 0.000 claims description 113
- 239000002775 capsule Substances 0.000 claims description 102
- 239000003814 drug Substances 0.000 claims description 88
- 208000018737 Parkinson disease Diseases 0.000 claims description 68
- 239000002552 dosage form Substances 0.000 claims description 24
- 206010012289 Dementia Diseases 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000029028 brain injury Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 230000004770 neurodegeneration Effects 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 208000019116 sleep disease Diseases 0.000 abstract description 11
- 208000022925 sleep disturbance Diseases 0.000 abstract description 11
- 239000008188 pellet Substances 0.000 description 160
- 239000011248 coating agent Substances 0.000 description 118
- 238000000576 coating method Methods 0.000 description 118
- 238000009472 formulation Methods 0.000 description 88
- 229940079593 drug Drugs 0.000 description 74
- 238000004090 dissolution Methods 0.000 description 62
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 51
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 208000012661 Dyskinesia Diseases 0.000 description 46
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 45
- 230000009467 reduction Effects 0.000 description 45
- 239000011230 binding agent Substances 0.000 description 38
- 239000004014 plasticizer Substances 0.000 description 35
- 206010016256 fatigue Diseases 0.000 description 34
- 238000000338 in vitro Methods 0.000 description 33
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 33
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 32
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 29
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 29
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 29
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 229940069328 povidone Drugs 0.000 description 27
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 26
- 239000001856 Ethyl cellulose Substances 0.000 description 25
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 25
- 229960001280 amantadine hydrochloride Drugs 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 25
- 239000012738 dissolution medium Substances 0.000 description 25
- 235000019325 ethyl cellulose Nutrition 0.000 description 25
- 229920001249 ethyl cellulose Polymers 0.000 description 25
- -1 tale Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 229940068196 placebo Drugs 0.000 description 22
- 239000000902 placebo Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 20
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 18
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 18
- 229960004502 levodopa Drugs 0.000 description 18
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 16
- 229920001223 polyethylene glycol Polymers 0.000 description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 15
- 229920001531 copovidone Polymers 0.000 description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 15
- 239000008108 microcrystalline cellulose Substances 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 13
- 229940057917 medium chain triglycerides Drugs 0.000 description 13
- 239000011148 porous material Substances 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 208000032140 Sleepiness Diseases 0.000 description 10
- 206010041349 Somnolence Diseases 0.000 description 10
- 230000036626 alertness Effects 0.000 description 10
- 239000004359 castor oil Substances 0.000 description 10
- 235000019438 castor oil Nutrition 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 10
- 230000037321 sleepiness Effects 0.000 description 10
- 239000000454 talc Substances 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 9
- 150000001860 citric acid derivatives Chemical class 0.000 description 9
- 125000005456 glyceride group Chemical group 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 229920003134 Eudragit® polymer Polymers 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 229960002805 amantadine sulfate Drugs 0.000 description 7
- MYWTWSQFJLXGGQ-UHFFFAOYSA-N amantadine sulfate Chemical compound OS(O)(=O)=O.C1C(C2)CC3CC2CC1(N)C3.C1C(C2)CC3CC2CC1(N)C3 MYWTWSQFJLXGGQ-UHFFFAOYSA-N 0.000 description 7
- 238000001125 extrusion Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000005563 spheronization Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 239000007963 capsule composition Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229920000058 polyacrylate Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 208000024453 abnormal involuntary movement Diseases 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000020937 fasting conditions Nutrition 0.000 description 4
- 230000009246 food effect Effects 0.000 description 4
- 235000021471 food effect Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 229920000178 Acrylic resin Polymers 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000019736 Cranial nerve disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 2
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 2
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 235000011967 chocolate pudding Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229940031954 dibutyl sebacate Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012734 extended-release (ER) formulation Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 125000005395 methacrylic acid group Chemical group 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000021058 soft food Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 1
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical class CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 208000008039 Secondary Parkinson Disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000019016 inability to swallow Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- NXMXPVQZFYYPGD-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate Chemical compound COC(=O)C=C.COC(=O)C(C)=C NXMXPVQZFYYPGD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015202356A AU2015202356B2 (en) | 2009-12-02 | 2015-05-05 | Amantadine compositions and methods of use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26605309P | 2009-12-02 | 2009-12-02 | |
| US61/266,053 | 2009-12-02 | ||
| PCT/US2010/058789 WO2011069010A2 (en) | 2009-12-02 | 2010-12-02 | Amantadine compositions and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015202356A Division AU2015202356B2 (en) | 2009-12-02 | 2015-05-05 | Amantadine compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2010325960A1 AU2010325960A1 (en) | 2012-06-21 |
| AU2010325960B2 AU2010325960B2 (en) | 2015-02-05 |
| AU2010325960C1 true AU2010325960C1 (en) | 2015-08-06 |
Family
ID=44115504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010325960A Active AU2010325960C1 (en) | 2009-12-02 | 2010-12-02 | Amantadine compositions and methods of use |
Country Status (9)
| Country | Link |
|---|---|
| US (24) | US8741343B2 (enExample) |
| EP (2) | EP3132793A1 (enExample) |
| JP (4) | JP5885668B2 (enExample) |
| CN (2) | CN106389381A (enExample) |
| AU (1) | AU2010325960C1 (enExample) |
| BR (1) | BR112012013487A2 (enExample) |
| CA (2) | CA2994873A1 (enExample) |
| MX (2) | MX365650B (enExample) |
| WO (1) | WO2011069010A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1845968A2 (en) | 2004-11-24 | 2007-10-24 | Neuromolecular Pharmaceuticals, Inc | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
| EP3132793A1 (en) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| CN103181914B (zh) * | 2011-12-27 | 2014-11-05 | 上海复星医药产业发展有限公司 | 盐酸美金刚缓释胶囊及其制备方法 |
| CN103417483B (zh) * | 2012-05-25 | 2017-09-12 | 杭州赛利药物研究所有限公司 | 盐酸美金刚缓释干混悬剂及其制备方法 |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
| SI3215132T1 (sl) * | 2014-11-04 | 2021-11-30 | Adamas Pharmaceuticals, Inc. | Amantadin za izboljšanje hoje pri multipli sklerozi |
| EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| CN106580923A (zh) * | 2016-12-09 | 2017-04-26 | 河南中帅医药科技股份有限公司 | 盐酸美金刚缓释微丸、胶囊及其制备方法 |
| WO2019040748A1 (en) * | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE |
| US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
| US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| CN112076174B (zh) * | 2020-09-04 | 2023-07-04 | 四川省百草生物药业有限公司 | 一种盐酸金刚乙胺片及其制备方法 |
| US12396964B2 (en) * | 2021-08-26 | 2025-08-26 | Shinkei Therapeutics, Inc. | Amantadine hydrochloride for the treatment of traumatic brain injury |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050267176A1 (en) * | 2004-02-18 | 2005-12-01 | Sepracor Inc. | Dopamine-agonist combination therapy for improving sleep quality |
| WO2006058236A2 (en) * | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
| US20060142398A1 (en) * | 2004-11-23 | 2006-06-29 | Went Gregory T | Method and composition for adminstering an NMDA receptor antagonist to a subject |
| US20080227743A1 (en) * | 2007-03-13 | 2008-09-18 | Jack Nguyen | Compositions and Kits for Treating Influenza |
Family Cites Families (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3152180A (en) | 1960-08-25 | 1964-10-06 | Studiengesellschaft Kohle Mbh | Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines |
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| GB1175820A (en) | 1966-02-18 | 1969-12-23 | Upjohn Co | Amino-Adamantane Derivatives |
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| US4284444A (en) | 1977-08-01 | 1981-08-18 | Herculite Protective Fabrics Corporation | Activated polymer materials and process for making same |
| US4148896A (en) | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4346112A (en) | 1981-06-29 | 1982-08-24 | University Patents Inc. | Composition and method for treating patients having Parkinson's Disease |
| JPS584718A (ja) | 1981-06-30 | 1983-01-11 | Nippon Chibagaigii Kk | 新規適応症に用うる医薬製剤 |
| DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
| JPS61502760A (ja) | 1984-07-24 | 1986-11-27 | キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド | 粘着性経皮投与層 |
| US4769027A (en) * | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| EP0241809B1 (de) | 1986-04-16 | 1990-08-08 | ASTA Pharma Aktiengesellschaft | Synergistische Kombination von Amantadin und Selegilin |
| GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| US5330766A (en) * | 1989-01-06 | 1994-07-19 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| ATE94384T1 (de) | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
| DK469989D0 (da) | 1989-09-22 | 1989-09-22 | Bukh Meditec | Farmaceutisk praeparat |
| WO1991006291A1 (fr) | 1989-10-26 | 1991-05-16 | Nippon Shinyaku Co., Ltd. | Preparation a liberation entretenue |
| IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5192550A (en) * | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
| US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
| US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US6764697B1 (en) | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
| DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| US5358721A (en) * | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
| WO1995003052A1 (en) | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
| KR100241300B1 (ko) | 1993-11-16 | 2000-03-02 | Sheldon A. Schaffer | 활성물질의 조절된 방출성을 갖는 소포 |
| US5395626A (en) * | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
| DE4413350A1 (de) | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
| US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
| US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
| US5677349A (en) | 1995-04-27 | 1997-10-14 | Gilad; Gad M. | Agmatine for the treatment of neurotrauma and neurodegenerative diseases |
| DE19528388A1 (de) | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| AU3404997A (en) * | 1996-05-31 | 1998-01-05 | Euro-Celtique S.A. | Sustained release oxycodone formulations with no fed/fast effect |
| DE69733081T2 (de) * | 1996-08-23 | 2006-05-11 | Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US5919826A (en) * | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
| CA2269707C (en) * | 1996-10-25 | 2005-08-16 | Edward M. Rudnic | Soluble form osmotic dose delivery system |
| DE19644998C1 (de) | 1996-10-30 | 1998-06-10 | Hanns Prof Dr Ludwig | Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier |
| US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| JPH10203966A (ja) | 1996-11-21 | 1998-08-04 | Takeda Chem Ind Ltd | 徐放性マイクロカプセルおよびその製造法 |
| KR20000010907A (ko) | 1997-03-11 | 2000-02-25 | 야스따까 이시이 | 아다만탄 유도체 및 그의 제조 방법 |
| US5849800A (en) * | 1997-03-28 | 1998-12-15 | The Penn State Research Foundation | Use of amantadine for treatment of Hepatitis C |
| DK0870757T3 (da) | 1997-04-10 | 2002-07-15 | Pfizer | Fluorsubstituerede adamantanderivater |
| MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| US6046232A (en) | 1997-10-17 | 2000-04-04 | Centaur Pharmaceuticals, Inc. | α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same |
| FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| US6251430B1 (en) * | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
| EP1140012B1 (en) | 1998-12-17 | 2004-03-03 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| JP2002535353A (ja) | 1999-01-29 | 2002-10-22 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク | 医薬品組成物 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| MXPA01008849A (es) | 1999-03-03 | 2003-07-21 | Optinose As | Dispositivo de administracion nasal. |
| SE9901077D0 (sv) | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| JP2003509439A (ja) | 1999-09-14 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | 水性コーティングされたビーズレットの製法 |
| EP2295043A1 (en) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| KR100738276B1 (ko) * | 1999-12-09 | 2007-07-12 | 알자 코포레이션 | 항바이러스성 약제 |
| KR100653153B1 (ko) | 1999-12-22 | 2006-12-01 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 수용성 중합체의 입체장애 유도체 |
| US6753011B2 (en) | 2000-01-14 | 2004-06-22 | Osmotica Corp | Combined diffusion/osmotic pumping drug delivery system |
| US6491949B2 (en) | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
| US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
| BR0116001A (pt) | 2000-12-07 | 2004-07-06 | Neuromolecular Inc | Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda |
| US20040122090A1 (en) | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| JP5005157B2 (ja) † | 2001-03-13 | 2012-08-22 | ペンウェスト ファーマシューティカルズ カンパニー | 時間治療（ｃｈｒｏｎｏｔｈｅｒａｐｅｕｔｉｃ）投与形態 |
| US20060198815A1 (en) | 2001-03-19 | 2006-09-07 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained release |
| WO2002078615A2 (en) | 2001-04-02 | 2002-10-10 | Panorama Research, Inc. | Antioxidant nitroxides and nitrones as therapeutic agents |
| DE10129265A1 (de) | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US20030045577A1 (en) * | 2001-08-15 | 2003-03-06 | Madhat Maher N. | Method for preventing infectious respiratory diseases |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| US20030118647A1 (en) * | 2001-12-04 | 2003-06-26 | Pawan Seth | Extended release tablet of metformin |
| US20050271708A1 (en) | 2002-03-05 | 2005-12-08 | Thombre Avinash G | Palatable controlled-release formulation for companion animals |
| WO2003077897A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| EP1499289B1 (en) | 2002-03-29 | 2008-07-23 | Alza Corporation | Volume efficient controlled release dosage form |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| IL165255A0 (en) | 2002-05-31 | 2005-12-18 | Lundbeck & Co As H | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease |
| DE10224170A1 (de) | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| ATE376854T1 (de) | 2002-06-26 | 2007-11-15 | Alza Corp | Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme |
| US20050208132A1 (en) * | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
| EP1524981B1 (en) | 2002-07-29 | 2009-03-11 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| DE10237082B4 (de) * | 2002-08-09 | 2014-12-31 | Sartorius Stedim Biotech Gmbh | Verfahren und Vorrichtung zur biotechnologischen Herstellung von Wertstoffen |
| AU2003284005B2 (en) | 2002-10-03 | 2009-12-17 | Forest Laboratories Holdings Limited | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders |
| GEP20094759B (en) | 2002-10-24 | 2009-08-25 | Merz Pharma Gmbh & Co Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| US20060024366A1 (en) | 2002-10-25 | 2006-02-02 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| US20040097484A1 (en) | 2002-11-14 | 2004-05-20 | Marc Cantillion | Once a day galantamine pharmaceutical compositions and methods of use |
| US20100092562A1 (en) | 2002-11-26 | 2010-04-15 | Hollenbeck R Gary | Sustained-release drug delivery compositions and methods |
| EP1572164A2 (en) * | 2002-12-18 | 2005-09-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| WO2004056335A2 (es) * | 2002-12-23 | 2004-07-08 | Osmotica Costa Rica Sociedad Anonima | Dispositivo de liberación que contiene venlafaxina y memantina |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| AR043467A1 (es) * | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
| US20050065219A1 (en) | 2003-03-27 | 2005-03-24 | Lipton Stuart A. | Treatment of demyelinating conditions |
| US20050124701A1 (en) | 2003-06-11 | 2005-06-09 | Went Gregory T. | Method of targeting a therapeutic agent |
| MXPA05012810A (es) | 2003-06-16 | 2006-02-13 | Allergan Inc | Formas de dosis oral de memantina. |
| WO2005027878A1 (en) | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Delayed released dosage forms |
| CA2539182A1 (en) | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
| US20080026081A1 (en) | 2003-11-21 | 2008-01-31 | Axel Unterbeck | Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate |
| US20050119249A1 (en) | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US20050232990A1 (en) | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
| CA2551946A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
| WO2005072125A2 (en) | 2004-01-16 | 2005-08-11 | Massachusetts Institute Of Technology | Composite materials for controlled release of water soluble products |
| CA2554959A1 (en) | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| US20050209218A1 (en) * | 2004-02-13 | 2005-09-22 | Meyerson Laurence R | Methods and compositions for the treatment of psychiatric conditions |
| AU2005215767A1 (en) | 2004-02-13 | 2005-09-01 | Adamas Pharmaceuticals, Inc. | Combination of an NMDA receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other CNS disorders |
| WO2006009769A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| EP1765305A4 (en) | 2004-07-09 | 2008-06-04 | Drugtech Corp | REGULATED PHASE COMPOSITION TECHNOLOGY USED AS ENHANCED MEDICATION PROTECTION METHOD |
| US8609198B2 (en) * | 2004-07-21 | 2013-12-17 | Hewlett-Packard Development Company, L.P. | Pharmaceutical dose form with a patterned coating and method of making the same |
| WO2006024018A2 (en) * | 2004-08-24 | 2006-03-02 | Neuromolecular Pharmaceuticals, Inc. | Compositions for treating nociceptive pain |
| WO2006042249A2 (en) * | 2004-10-08 | 2006-04-20 | Neuromolecular Pharmaceuticals, Inc. | Methods and compositions for treating migraine pain |
| RU2404750C2 (ru) * | 2004-11-23 | 2010-11-27 | Адамас Фармасьютикалс, Инк. | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту |
| AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
| US8574626B2 (en) * | 2004-12-03 | 2013-11-05 | Osmotica Kereskedelmi és Szolgáltató KFT | Osmotic device containing amantadine and an osmotic salt |
| US8252331B2 (en) * | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
| US20090208579A1 (en) | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| CA2596035A1 (en) | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
| US20080279819A1 (en) * | 2005-02-15 | 2008-11-13 | Adamas Pharmaceuticals, Inc. | Combinations Therapy for Treatment of Demyelinating Conditions |
| AU2006244297A1 (en) | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of CNS disorders |
| US20060280795A1 (en) | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
| WO2007036952A2 (en) | 2005-07-01 | 2007-04-05 | Rubicon Research Pvt Ltd. | Novel sustained release dosage form |
| US7951760B2 (en) * | 2005-07-29 | 2011-05-31 | Chevron Oronite S.A. | Overbased alkali metal alkylhydroxybenzoates having low crude sediment |
| RU2385712C2 (ru) | 2005-08-24 | 2010-04-10 | Рубикон Рисёч Пвт Лтд. | Рецептура с контролируемым высвобождением |
| US20070104778A1 (en) | 2005-11-07 | 2007-05-10 | Hongxia Zeng | Controlled-release emulsion compositions |
| CA2648280C (en) | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| EP2034980A1 (en) * | 2006-05-19 | 2009-03-18 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of viral infections |
| US20080089861A1 (en) * | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| ATE510538T1 (de) * | 2006-08-11 | 2011-06-15 | Univ Johns Hopkins | Zusammensetzungen und verfahren für nervenschutz |
| AU2007291509B2 (en) | 2006-08-30 | 2013-05-02 | Jagotec Ag | Controlled release oral dosage formulations comprising a core and one or more barrier layers |
| EP1961414A1 (en) | 2007-02-21 | 2008-08-27 | FUJIFILM Manufacturing Europe B.V. | A controlled release composition comprising a recombinant gelatin |
| KR101122469B1 (ko) * | 2007-04-02 | 2012-07-12 | 파킨슨즈 인스티튜트 | 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물 |
| US20100092554A1 (en) | 2007-04-24 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| WO2008151071A1 (en) | 2007-05-30 | 2008-12-11 | Neos Therapeutics, Lp | Modifying drug release in suspensions of ionic resin systems |
| NZ580972A (en) | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| US8637080B2 (en) | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
| US20090041820A1 (en) | 2007-08-07 | 2009-02-12 | Wu Margaret M | Functional polymer compositions |
| JP5204846B2 (ja) | 2007-09-21 | 2013-06-05 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | エタノールの影響に対して耐性を有する非オピオイド薬のｐＨ依存性制御放出医薬組成物 |
| US20090196908A1 (en) | 2008-01-31 | 2009-08-06 | Der-Yang Lee | Edible film-strips with modified release active ingredients |
| JP2010040238A (ja) * | 2008-08-01 | 2010-02-18 | Panasonic Corp | プラズマディスプレイパネルの製造方法 |
| US20110142905A1 (en) | 2008-08-14 | 2011-06-16 | Bioneer A/S | Coated tablets with remaining degradation surface over the time |
| US20100159001A1 (en) | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| US20100221328A1 (en) * | 2008-12-31 | 2010-09-02 | Wertz Christian F | Sustained-release formulations |
| US20130059008A1 (en) | 2009-01-23 | 2013-03-07 | Jeffrey L. Atkinson | Drying methods for tuning microparticle properties |
| WO2010105672A1 (en) | 2009-03-18 | 2010-09-23 | Evonik Röhm Gmbh | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients |
| EP2411083A4 (en) | 2009-03-23 | 2013-11-13 | Micell Technologies Inc | MEDICAL ACTIVE COMPOSITION DEVICE |
| WO2010115015A1 (en) | 2009-04-03 | 2010-10-07 | Coating Place, Inc. | Modified-release pharmaceutical drug composition |
| EP3132793A1 (en) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| EP2706641A1 (en) | 2012-09-05 | 2014-03-12 | Siemens Aktiengesellschaft | Method to provide primary control power by an energy storage system |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| WO2019040748A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE |
-
2010
- 2010-12-02 EP EP16176422.0A patent/EP3132793A1/en not_active Withdrawn
- 2010-12-02 CA CA2994873A patent/CA2994873A1/en not_active Abandoned
- 2010-12-02 JP JP2012542198A patent/JP5885668B2/ja active Active
- 2010-12-02 MX MX2015014117A patent/MX365650B/es unknown
- 2010-12-02 CA CA2782556A patent/CA2782556C/en active Active
- 2010-12-02 CN CN201610187300.4A patent/CN106389381A/zh active Pending
- 2010-12-02 BR BR112012013487A patent/BR112012013487A2/pt not_active Application Discontinuation
- 2010-12-02 US US12/959,321 patent/US8741343B2/en active Active
- 2010-12-02 WO PCT/US2010/058789 patent/WO2011069010A2/en not_active Ceased
- 2010-12-02 MX MX2012006320A patent/MX2012006320A/es active IP Right Grant
- 2010-12-02 AU AU2010325960A patent/AU2010325960C1/en active Active
- 2010-12-02 EP EP10835150.3A patent/EP2506709B2/en active Active
- 2010-12-02 CN CN2010800629140A patent/CN102883601A/zh active Pending
-
2014
- 2014-05-01 US US14/267,597 patent/US20140242163A1/en not_active Abandoned
- 2014-10-24 US US14/523,535 patent/US20150045438A1/en not_active Abandoned
- 2014-10-24 US US14/523,688 patent/US20150051292A1/en not_active Abandoned
- 2014-10-24 US US14/523,589 patent/US20150045439A1/en not_active Abandoned
- 2014-10-24 US US14/523,607 patent/US20150045448A1/en not_active Abandoned
- 2014-10-24 US US14/523,477 patent/US20150045446A1/en not_active Abandoned
- 2014-10-24 US US14/523,674 patent/US20150057355A1/en not_active Abandoned
- 2014-10-24 US US14/523,565 patent/US20150045447A1/en not_active Abandoned
-
2015
- 2015-02-12 JP JP2015025394A patent/JP6038203B2/ja active Active
- 2015-09-17 US US14/857,509 patent/US20160256414A1/en not_active Abandoned
- 2015-09-23 US US14/863,067 patent/US20160263055A1/en not_active Abandoned
- 2015-09-23 US US14/863,002 patent/US20160263053A1/en not_active Abandoned
- 2015-09-23 US US14/863,051 patent/US20160263054A1/en not_active Abandoned
- 2015-09-23 US US14/863,035 patent/US20160151307A1/en not_active Abandoned
- 2015-09-25 US US14/865,773 patent/US20160263057A1/en not_active Abandoned
- 2015-09-25 US US14/865,736 patent/US20160263056A1/en not_active Abandoned
-
2016
- 2016-11-01 JP JP2016214360A patent/JP6316376B2/ja active Active
-
2017
- 2017-02-09 US US15/428,899 patent/US9867791B2/en active Active
- 2017-02-09 US US15/428,980 patent/US9867792B2/en active Active
- 2017-02-09 US US15/428,946 patent/US20170151186A1/en not_active Abandoned
- 2017-02-09 US US15/428,878 patent/US9877933B2/en active Active
- 2017-02-09 US US15/428,920 patent/US20170151185A1/en not_active Abandoned
- 2017-02-10 US US15/430,084 patent/US9867793B2/en active Active
-
2018
- 2018-03-27 JP JP2018060223A patent/JP2018100306A/ja not_active Withdrawn
- 2018-05-21 US US15/985,300 patent/US20180263928A1/en not_active Abandoned
-
2019
- 2019-12-26 US US16/727,263 patent/US11197835B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050267176A1 (en) * | 2004-02-18 | 2005-12-01 | Sepracor Inc. | Dopamine-agonist combination therapy for improving sleep quality |
| US20060142398A1 (en) * | 2004-11-23 | 2006-06-29 | Went Gregory T | Method and composition for adminstering an NMDA receptor antagonist to a subject |
| WO2006058236A2 (en) * | 2004-11-24 | 2006-06-01 | Neuromolecular Pharmaceuticals, Inc. | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
| US20080227743A1 (en) * | 2007-03-13 | 2008-09-18 | Jack Nguyen | Compositions and Kits for Treating Influenza |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11197835B2 (en) | Method of administering amantadine prior to a sleep period | |
| US11903908B2 (en) | Methods of administering amantadine | |
| AU2015202356B2 (en) | Amantadine compositions and methods of use | |
| HK1234346A (en) | Amantadine compositions and methods of use | |
| HK1234346A1 (en) | Amantadine compositions and methods of use | |
| HK1176818B (en) | Amantadine compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 APR 2015 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 APR 2015 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: ADAMAS PHARMA, LLC Free format text: FORMER OWNER(S): ADAMAS PHARMACEUTICALS, INC. |